Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
12:56pm, Tuesday, 27'th Feb 2024
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
08:00am, Friday, 12'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 21'st Dec 2023
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:32pm, Monday, 13'th Nov 2023
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript
02:32am, Wednesday, 08'th Nov 2023
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - C
CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
08:00am, Tuesday, 31'st Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting
08:00am, Monday, 30'th Oct 2023
- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally
CytomX Therapeutics to Present at Upcoming September Investor Conferences
04:05pm, Tuesday, 05'th Sep 2023
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that ma
CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Friday, 25'th Aug 2023
The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript
10:57pm, Tuesday, 08'th Aug 2023
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chie
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
06:57pm, Tuesday, 08'th Aug 2023
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.
CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
08:00am, Tuesday, 01'st Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
04:05pm, Thursday, 01'st Jun 2023
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea
CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript
11:13pm, Tuesday, 09'th May 2023
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Accounting Sean McCarthy - CEO, Chairman Conference Ca
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
07:07pm, Tuesday, 09'th May 2023
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago.
